JP2011500713A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500713A5
JP2011500713A5 JP2010530110A JP2010530110A JP2011500713A5 JP 2011500713 A5 JP2011500713 A5 JP 2011500713A5 JP 2010530110 A JP2010530110 A JP 2010530110A JP 2010530110 A JP2010530110 A JP 2010530110A JP 2011500713 A5 JP2011500713 A5 JP 2011500713A5
Authority
JP
Japan
Prior art keywords
cancer
compound
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530110A
Other languages
English (en)
Japanese (ja)
Other versions
JP5496899B2 (ja
JP2011500713A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/080163 external-priority patent/WO2009052287A1/en
Publication of JP2011500713A publication Critical patent/JP2011500713A/ja
Publication of JP2011500713A5 publication Critical patent/JP2011500713A5/ja
Application granted granted Critical
Publication of JP5496899B2 publication Critical patent/JP5496899B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530110A 2007-10-16 2008-10-16 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン Active JP5496899B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16
US60/980,397 2007-10-16
PCT/US2008/080163 WO2009052287A1 (en) 2007-10-16 2008-10-16 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014043175A Division JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン

Publications (3)

Publication Number Publication Date
JP2011500713A JP2011500713A (ja) 2011-01-06
JP2011500713A5 true JP2011500713A5 (enExample) 2011-12-01
JP5496899B2 JP5496899B2 (ja) 2014-05-21

Family

ID=40251685

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010530110A Active JP5496899B2 (ja) 2007-10-16 2008-10-16 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン
JP2014043175A Active JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014043175A Active JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン

Country Status (40)

Country Link
US (4) US8268800B2 (enExample)
EP (2) EP2207786B1 (enExample)
JP (2) JP5496899B2 (enExample)
KR (1) KR101543049B1 (enExample)
CN (1) CN101827856B (enExample)
AT (1) ATE548374T1 (enExample)
BR (1) BRPI0818672B8 (enExample)
CA (1) CA2702274C (enExample)
CO (1) CO6270330A2 (enExample)
CR (1) CR11427A (enExample)
CY (3) CY1112781T1 (enExample)
DK (1) DK2207786T3 (enExample)
EA (1) EA018757B1 (enExample)
EC (1) ECSP10010095A (enExample)
ES (2) ES2384011T3 (enExample)
FI (2) FIC20230039I1 (enExample)
FR (2) FR23C1051I2 (enExample)
GT (1) GT201000088A (enExample)
HR (1) HRP20120419T1 (enExample)
HU (2) HUS2300044I1 (enExample)
IL (1) IL204732A (enExample)
JO (1) JO2778B1 (enExample)
LT (2) LTC2207786I2 (enExample)
LU (2) LUC00327I2 (enExample)
ME (1) ME00997B (enExample)
MX (1) MX2010004109A (enExample)
MY (1) MY147970A (enExample)
NI (1) NI201000055A (enExample)
NL (2) NL301256I2 (enExample)
NO (2) NO2023048I1 (enExample)
NZ (1) NZ584229A (enExample)
PL (1) PL2207786T3 (enExample)
PT (1) PT2207786E (enExample)
RS (1) RS52323B (enExample)
SA (1) SA08290661B1 (enExample)
SI (1) SI2207786T1 (enExample)
TW (1) TWI445539B (enExample)
UA (1) UA99476C2 (enExample)
WO (1) WO2009052287A1 (enExample)
ZA (1) ZA201002178B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
EP2416781B1 (en) * 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
US9834576B2 (en) * 2013-10-29 2017-12-05 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
CN109789155B (zh) 2015-12-03 2025-02-07 免疫规划公司 含有地西他滨、5-氮杂胞苷和四氢尿苷的组合物以及其用途
WO2017158396A1 (en) * 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
KR20200118827A (ko) 2018-02-02 2020-10-16 마베릭스 온콜로지, 잉크. 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
CN113227755B (zh) * 2018-08-28 2025-06-27 上海宜晟生物科技有限公司 测定准确度改善
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
KR102280330B1 (ko) * 2018-10-19 2021-07-21 인터올리고 주식회사 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
US12448624B2 (en) 2018-10-19 2025-10-21 Interoligo Corporation Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
AU2020363412B2 (en) 2019-10-08 2026-03-12 Taiho Pharmaceutical Co., Ltd. 2'-deoxy-2',2'-difluorotetrahydrouridines with high purity and methods of making the same
LT4069254T (lt) 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną
AU2022244240A1 (en) * 2021-03-26 2023-10-05 The Cleveland Clinic Foundation Treatment of rna virus infection with a cytidine deaminase inhibitor
AU2022274071A1 (en) * 2021-05-11 2024-01-04 Janssen Pharmaceutica Nv Combination therapies
KR20240006638A (ko) * 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
US20240279266A1 (en) * 2021-05-29 2024-08-22 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
MX2024004801A (es) 2021-10-19 2024-06-28 Akirabio Inc Composiciones que comprenden análogos de 2'- desoxicitidina, y uso de las mismas para el tratamiento de anemia de células falciformes, talasemia y cánceres.
WO2023076332A1 (en) * 2021-11-01 2023-05-04 St. John's University Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
JP2025529240A (ja) 2022-08-31 2025-09-04 大鵬薬品工業株式会社 トリナパント、セダズリジン及びデシタビンによるｔ細胞リンパ腫の治療のための併用療法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) * 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0160079B1 (en) 1983-10-26 1990-01-31 GREER, Sheldon B. Method and materials for sensitizing neoplastic tissue to radiation
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
EP0543976A4 (en) 1991-04-23 1993-11-10 Oglevee, Ltd. In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) * 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
EP0641352B1 (en) * 1993-02-23 1997-06-04 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
AU6081294A (en) * 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) * 1995-03-01 1996-09-06 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) * 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
ES2273672T3 (es) * 1999-03-01 2007-05-16 Halogenetics, Inc. Uso de composiciones que comprenden cldc como radiosensibilizadores en el tratamiento de enfermedades neoplasticas.
US6933287B1 (en) * 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
WO2001013789A1 (en) 1999-08-26 2001-03-01 Aortech International Plc Improvements relating to catheter positioning
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN102241720B (zh) * 2000-11-29 2014-01-29 三井化学株式会社 L-核酸衍生物及其合成方法
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
EP2322534A1 (en) 2001-05-18 2011-05-18 Rakesh Kumar Antiviral nucleosides
US8207142B2 (en) * 2001-07-31 2012-06-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitor of DNA methylation
EP1480982A4 (en) 2002-02-14 2007-08-01 Pharmasset Inc MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2003278904A1 (en) 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2005115410A2 (en) * 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN101076536A (zh) 2004-07-30 2007-11-21 药华医药股份有限公司 β－核苷的立体选择性合成
US20060173174A1 (en) 2004-12-08 2006-08-03 Anne-Ruth Born Difluoronucleosides and process for preparation thereof
WO2008085611A2 (en) 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
EP2416781B1 (en) * 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer

Similar Documents

Publication Publication Date Title
HRP20120419T1 (hr) Fluoro deoksitetrahidrouridini kao inhibitori citidin deaminaze
JP2014177455A5 (enExample)
JP2012522842A5 (enExample)
JP2013518107A5 (enExample)
JP2008528671A5 (enExample)
JP2017511311A5 (enExample)
JP2011501962A5 (enExample)
JP2010504079A5 (enExample)
JP2010523670A5 (enExample)
JP2015536964A5 (enExample)
JP2009543802A5 (enExample)
JP2015512860A5 (enExample)
JP2009536191A5 (enExample)
JP2010540556A5 (enExample)
JP2023545096A5 (enExample)
JP2012522841A5 (enExample)
JP2017527582A5 (enExample)
JP2015536954A5 (enExample)
JP2017526662A5 (enExample)
JP2008536853A5 (enExample)
JP2016501838A5 (enExample)
JP2012509265A5 (enExample)
JP2011509956A5 (enExample)
JP2011518153A5 (enExample)
JP2021505526A5 (enExample)